Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04652687 · ClinicalTrials.gov registry record
VIA Disc NP Registry
A clinical trial, sponsored by VIVEX Biologics.
- Terminated
- Registry status
- 83
- Enrollment target
NCT04652687: Clinical Trial study, sponsored by VIVEX Biologics.
NCT04652687 is a clinical trial that was terminated before completion, run by VIVEX Biologics. The registered enrollment target is 83 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04652687 was terminated before completion, sponsored by VIVEX Biologics.
- TERMINATED
- Registry status
- 83 participants
- Enrollment target
Study Summary
Registry is to observe and trend patterns of care and outcomes for patients treated with VIA Disc NP.
Primary Outcome
Change in scores from Oswestry Disability Index (ODI). An index comprising of ten categories of function to quantify disability due to back pain.
Interventions
- OTHER VIA Disc NP (HCT/P)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2020-05-03 |
| Est. Completion | 2024-03-05 |
Why NCT04652687 stopped before completion
NCT04652687 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 83 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which VIA Disc NP (HCT/P) is the first listed.
NCT04652687 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04652687 about?
NCT04652687 is a clinical study titled "VIA Disc NP Registry". Registry is to observe and trend patterns of care and outcomes for patients treated with VIA Disc NP.
What is the current status of trial NCT04652687?
This trial is currently terminated. The enrollment target is 83 participants. The study started on 2020-05-03. Estimated completion is 2024-03-05.
What interventions are being tested in trial NCT04652687?
The interventions under investigation include: VIA Disc NP (HCT/P) (OTHER).
Who is sponsoring clinical trial NCT04652687?
This trial is sponsored by VIVEX Biologics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI